Company intelligence / Profile preview
EvolveImmune Therapeutics
Branford, Connecticut, United Statesevolveimmune.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company is developing novel T-cell engagers with integrated CD2 co-stimulation. Lead candidate EVOLVE104 has shown promising preclinical results for solid tumors with favorable pharmacokinetic and toxicity profiles. EVOLVE205 is being developed for hematologic tumors.
- Therapeutic areas
- Oncology
- Modalities
- Multifunctional biotherapeuticsT-cell engagersAntibody-based therapies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
AbbVieBristol Myers Squibb
Beyond the preview
Go deeper on EvolveImmune Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EvolveImmune Therapeutics.